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The capture of visible debris by distal cerebral
protection filters during carotid artery stenting:
Is it predictable?
L. Richard Sprouse II, MD,a, Patrick Peeters, MD,b and Marc Bosiers, MD,c Norfolk, Va; and Bonheiden
and Dendermonde, Belgium
Objectives: Neurologic complications during carotid artery stenting (CAS) are most clearly associated with embolization
of visible debris. Distal filter devices may provide cerebral protection by capturing clinically significant debris. However,
they increase procedural time and expense and have their own set of complications. The current study was undertaken to
identify the clinical factors predictive for the presence or absence of visible debris captured by distal filter devices during
CAS.
Methods: Patients undergoing CAS with use of a distal filter device (n  279) were prospectively entered into an
investigational carotid registry. Recorded variables were classified as patient-, lesion-, or procedure-related. The filter was
assessed for visible debris in each case. The odds ratio (OR) and 95% confidence interval (CI) were determined for each
variable to predict visible debris. The ability of each variable to predict the absence of visible debris was assessed by
calculating the individual negative predictive value (NPV).
Results: Visible debris was present in 169 filters (60.3%). There was an increased risk of visible debris found with several
variables (OR, 95% CI): hypertension (2.9, 1.7 to 5.2), hypercholesterolemia (2.3, 1.4 to 3.9), stent diameter >9 mm
(16.6, 9.0 to 30.0), and any neurologic event (4.2, 1.5 to 9.9). The NPV failed to exceed 0.80 (80%) for any variable. The
NPV of the variables with a significantly elevated OR was as follows: hypertension (0.60), hypercholesterolemia (0.52),
stent diameter >9mm (0.75), and any neurologic event (0.38).
Conclusions: Several clinical variables are associated with the presence of visible debris captured by distal filter devices. The
current study failed to identify any variables capable of consistently predicting the absence of visible debris. These findings
support the routine rather than the selective use of cerebral protection during CAS. (J Vasc Surg 2005;41:950-5.)Carotid artery angioplasty and stenting (CAS) is gain-
ing acceptance as an alternative to carotid endarterectomy
(CEA) for the treatment of cerebrovascular occlusive dis-
ease. Initially, the success of CAS was limited by a rather
high neurologic event rate related to cerebral emboliza-
tion.1-5 However, better results have recently been re-
ported with the use of cerebral protection devices (CPD)
that capture harmful debris and prevent embolization.6-10
Neurologic events during CAS are associated with the
degree of embolization, but not all debris is clinically
significant. Some evidence suggests that the size of the
particles is the most important factor.6,11,13-19 Larger em-
boli are clearly more dangerous than small emboli, which
are tolerated surprisingly well by the brain and are relatively
benign.
Distal protection filters have emerged as the most pop-
ular and, perhaps, the most intuitive among the available
CPDs. They are designed to capture significant macro-
scopic debris during CAS. Low neurologic event rates have
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950been reported with the use of distal filters in several
series.6-10
Although distal filters may reduce the complications
associated with CAS, several concerns have been cited with
their use. Tortuous anatomy and tight stenoses may pre-
clude safe deployment of the filter. Dissection, spasm, and
occlusion of the internal carotid artery (ICA) have all been
reported.7,10,20 Also, the filters may become trapped within
the struts of a stent during retrieval and become dislodged.
Finally, distal filters are expensive and may add time to the
procedure, which may offset the potential economic advan-
tages of CAS.
These issues raise the question of whether the routine
use of distal filters during CAS is warranted. The current
study was undertaken to determine if routinely available
clinical variables can be used to predict the presence or
absence of visible debris captured by distal filters during
CAS. If certain variables are identified that can consistently
predict macroembolization of visible debris, it may be
possible to identify those patients that benefit from CPDs
and those that do not, and the selective use of distal filters
during CAS may be justified.
METHODS
Patients. During a 13-month period, 397 patients
(290 men; mean age, 70.2  9.2) underwent elective
carotid revascularization and were entered into an investi-
gational carotid registry. All patients undergoing CAS con-
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the institutional review board. An endovascular interven-
tion was performed in 326 (82.1%), and a distal protection
filter was planned for 297 (74.8%). The filter was success-
fully deployed in 293 (73.8%), for a technical success rate of
98.6%. Complete data were available for 279 of the 293
patients, all of which had successful placement of an ICA
stent. These patients were included in the current study and
defined the primary study group.
Patients with carotid stenosis were offered CEA or CAS
if they had (1) symptomatic carotid stenosis 50%, (2)
asymptomatic carotid stenosis 70%, or (3) rapidly pro-
gressing carotid stenosis. Patients were excluded from CAS
if they had aortic arch anatomy that precluded access,
severely tortuous or elongated ICA, previous disabling
stroke or dementia, or associated intracranial pathology.
We have previously reported a specific list of our inclusion
and exclusion criteria.8
All patients underwent preoperative duplex ultrasound
scanning andmagnetic resonance angiography along with a
complete evaluation by a neurologist. These tests were used
to determine the degree of stenosis, rule out coexistent
proximal or distal disease, and assess the lesion for calcifi-
cation, thrombus, and ulceration. All findings were subse-
quently confirmed by digital subtraction angiography at the
time of CAS.
As a part of the carotid registry, a data sheet was created
for each patient. All data were collected prospectively and
entered into a computerized spreadsheet for analysis. The
variables assessed were classified as patient-related, lesion-
related, or procedure-related. The variables and their fre-
quency are listed in the Table.
Procedure details. The details of our CAS protocol
with distal filter placement are found in a previous report.8
In brief, clopidogrel (75 mg/d) and aspirin (81 mg/d) are
initiated at least 3 days before the intervention, and heparin
(5,000 U) is given after femoral sheath insertion.
The lesion is passed with the floppy-tip guidewire pro-
vided with the filter and delivery system, and the filter is
positioned at the base of the skull. A separate wire is not
used to cross the lesion. Predilation is rarely performed.
The stent is positioned at the site of the lesion with the
proximal end typically placed in the common carotid artery.
Postdilation is routinely performed with a 5 mm  2 cm
low-pressure angioplasty balloon. Completion digital sub-
traction angiography is performed and the femoral arteri-
otomy is closed percutaneously.
Equipment. Only self-expanding stents were used.
The types of stent deployed were Wallstent (Boston Scien-
tific, Natick, Mass), 210 (75.2%); Zilver (Cook Inc;
Bloomington, Ind), 41 (14.6%); SMART (Cordis Endo-
vascular; Miami, Fla) 25 (8.9%); and 3 others (0.1%). Mean
stent diameter was 8.8  1.1 mm and length was 24.6 
6.7 mm.
Five different commercially available filters were used
during the study period: FilterWire EX (Boston Scientific),
132 (47.3%); FilterWire EZ (Boston Scientific), 71
(25.4%); SpiderRX (ev3 Europe S.A.S., Paris, France), 40(14.3%); Angioguard XP (Cordis Endovascular), 33
(11.8%); and 4 others (0.1%). All filters had a pore size of
200 m.
Filter analysis. Each filter was inserted and removed
according to the instructions and with the delivery and
retrieval sheaths supplied by the specific manufacturer. The
filter was left inside the retrieval sheath until the procedure
was completed. At that time, it was carefully removed from
the sheath and assessed by the attending surgeon and
members of the surgical team for visible debris (Fig). If no
debris was immediately visible, the filter was washed and
suspended in a 10 mL glass container filled with saline
solution. The solution was then examined for visible debris.
Washing the filter assisted in identifying debris that was
obscured by blood on the surface of the filter. Microscopic
analysis of the filter was not performed.
Statistical analysis. Continuous variables were re-
ported as the mean of the group as whole, whereas cate-
goric variables were expressed as percentages or frequencies
within the primary study group. The difference in the
means between subgroups was analyzed by the Student’s
t test.
The association between the patient-, lesion-, and
Variables and frequency in relation to embolization for
patients undergoing carotid artery stenting with distal
cerebral protection filters
Variable
Frequency
(%) OR (95% CI) NPV
Patient-related
Age 70 149 (53) 1.1 (0.5-1.6) 0.52
Diabetes mellitus 58 (20) 1.9 (0.9-3.6) 0.57
Nicotine abuse 81 (29) 1.0 (0.6-1.8) 0.60
Obesity 12 (4) 1.3 (0.4-4.4) 0.60
Hypercholesterolemia 174 (62) 2.3 (1.4-3.9) 0.52
Hypertension 210 (75) 2.9 (1.7-5.2) 0.60
Symptomatic 180 (64) 1.6 (1.0-2.7) 0.52
Previous stroke 19 (6) 1.6 (0.4-3.9) 0.62
Right-sided lesion 149 (53) 0.8 (06-1.2) 0.53
Lesion-related
ICA diameter 6 mm 117 (41) 1.2 (0.6-2.1) 0.66
Lesion length 10 mm 44 (15) 0.6 (0.3-1.3) 0.68
Ulceration 86 (30) 1.3 (0.7-2.2) 0.53
Stenosis 50%-70% 13 (4) 1.5 (0.4-4.9) 0.60
Stenosis 70%-90% 200 (71) .57 (0.3-1.0) 0.69
Stenosis 90% 66 (23) 1.6 (0.9-3.0) 0.57
Thrombus 13 (4) 1.5 (0.4-4.9) 0.61
Calcification 111 (39) 1.1 (0.6-1.7) 0.52
Recurrent lesion 11 (3) .86 (0.4-3.2) 0.56
Procedure-related
FilterWire EX 132 (47) 1.3 (0.8-2.1) 0.58
FilterWire EZ 71 (25) 1.7 (0.9-2.5) 0.62
AngioGuard XP 33 (11) 1.0 (0.4-1.7) 0.60
ev3 SpiderRX 40 (14) 1.4 (0.7-2.2) 0.56
Stent diameter 9 mm 145 (51) 16.6 (9.0-30) 0.75
Duration 30 min 177 (63) 1.6 (0.9-2.3) 0.68
TIA 9 (3) 4.7 (0.5-28) 0.59
Major/minor stroke 3 (1) 3.2 (0.6-8.9) 0.51
Neurologic event 12 (4) 4.2 (1.5-9.9) 0.38
OR, Odds ratio; NPV, negative predictive value; ICA, internal carotid
artery; TIA, transient ischemic attack.procedure-related variables with the presence or absence of
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analysis and expressed as the odds ratio (OR) and 95%
confidence interval (CI). In all instances, P .05 indicated
a statistically significant difference.
The ability of each variable to predict the absence of
debris was assessed by calculating the negative predictive
value (NPV) in each case. A NPV of 0.95 was defined as
clinically acceptable.
RESULTS
The frequency of each of the patient-, lesion-, and
procedure-related variable is listed in the Table. Of note,
hypertension was present in 210 patients (75.1%) and was
the most common comorbidity. Symptoms were present in
180 (64.5%) and most often consisted of a transient isch-
emic attack. The difference between the severity of the
stenosis in symptomatic (78.4%) versus asymptomatic pa-
tients (81.5%) was not significant (P  .05).
Neurologic events occurred in 12 (4.3%) patients dur-
Visible debris captured by a distal filter during carotid artery
stenting.ing the procedure and consisted of transient ischemic attackin 9, minor stroke in 2, and major stroke in 1. Visible debris
was present in the filter in 10 (83.3%) of these patients. The
overall 30-day stroke/death rate was 2.1%
Visible debris was present in 169 of the filters (60.5%)in
the primary study group. The OR and 95% CI for each
variable are found in the Table. When assessed individually,
four variables were significantly associated with the pres-
ence of debris in the filter: hypercholesterolemia (P 
.001), hypertension (P  .025), stent 9 mm (P  .001),
and any neurologic event (P  .014).
Of the variables that were predictive for debris, two
were patient related (hypertension and hypercholesterol-
emia) and two were procedure related (stent diameter 9
mm and any neurologic event). No lesion-related variables
were independently associated with the presence or absence
of debris.
The NPV for each variable is found in the Table. None
of the variables were significantly associated with the ab-
sence of visible debris. The NPV was 95% predictive in
each case. The best predictor for the absence of visible
debris was stent diameter9mm (NPV, 0.75), but this still
fell short of the clinically acceptable level of 0.95.
DISCUSSION
Visible debris was found in 60% of the filters in the
current study. This suggests that the filter did not prevent
macroembolization in the remaining 40% andwas likely not
necessary for a successful outcome. Elimination of filter use
in this group of patients could lead to a reduction in the
expense of CAS. In addition, the occurrence of filter-
related complications could be avoided in a group of pa-
tients that do not benefit from filter use.
We identified several individual variables that were as-
sociated with the presence of visible debris in the filter. The
risk of visible debris was increased in patients with hyper-
tension and hypercholesterolemia but not by other the
patient-related variables, including the presence of symp-
toms or prior stroke. Our results did not confirm the report
by Mudra et al19 that found a correlation between the
presence of preoperative symptoms and the size of the
debris.
The two other factors predictive for visible debris were
procedure related. First, the risk of visible debris was signif-
icantly elevated when the stent diameter was 9 mm.
Others have shown that during CAS, most clinically rele-
vant embolization occurs during stent deployment and
dilation.12,21,22 The present study suggests that the degree
of embolization during stent deployment partly depends
on the stent diameter. The length of the stent was not
predictive, however.
The occurrence of any neurologic event during CAS
was the second procedure-related variable associated with
an increased risk of visible debris. This included transient
ischemic attack, minor stroke, andmajor stroke. Obviously,
this variable could not be used preoperatively to select
patients that would benefit from filter use, but it is an
interesting finding and raises several questions.
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tured, the risk of macroembolization is increased during
the unprotected phases of the procedure and this may be
responsible for the neurologic events. For example, wire
passage is associated with a relatively low risk of macroem-
bolization; however, in some cases this may not be true and
embolization can occur during the steps of CAS that are
usually regarded as benign.12,21,22 It is also possible that
the filter does not capture all clinically significant debris. In
fact, it has been shown previously that some debris can
escape the filter and embolize distally.18,21
It should be mentioned that the other procedure-
related variables were not significantly associated with the
capture of visible debris. The OR for each type of distal
filter used during the study was similar. In addition, the
presence of visible debris was not related to the type of stent
that was deployed. However, the statistical power of these
findings is limited because an equal number of each filter
and stent was not used. The failure to detect a difference
may have been due to an inadequate comparison secondary
to the relatively small number of the less commonly used
filters and stents. Finally, the duration of the procedure was
not predictive for visible debris.
Interestingly, none of the lesion-related variables, in-
cluding the degree of stenosis or presence of thrombus,
ulceration, or calcification, were independently predictive
for the presence or absence of visible debris. Although the
OR was elevated for each of these, it was not statistically
significant. In addition, the absence of “high-risk” lesion-
related variables was not predictive for the absence of visible
debris. In other words, visible debris was almost as likely to
occur in cases where there the stenosis was less severe and
there was no ulceration, calcification, or thrombus.
To some extent, our findings differ with a previous
experimental study that demonstrated an direct relation-
ship between the risk macroembolization and degree of
stenosis in a carotid plaque model.21,23 We are unable to
explain the disagreement but may safely conclude that in a
large clinical series, the presence of visible debris in distal
filters was not predictable by lesion characteristics alone.
It is possible that additional lesion-related characteris-
tics, not assessed in this study, are predictive for the capture
of visible debris during CAS. For example, the utility of the
gray-scale median index is currently being investigated as a
means to predict embolization.24 However, measurement
of gray-scale median has not gained widespread acceptance
and we do not use it to assess carotid lesions prior to CAS.
Until further data are available, routine measurement of the
gray-scale median index does not appear warranted.
Although several variables were associated with the
presence of visible debris, none of the variables assessed
were able to predict the absence of visible debris in the
filter. A primary goal of the current study was to identify a
group of patients who, on the basis of on patient-, lesion-,
or procedure-related variables, were unlikely to benefit
from filter use.
Although the exact relationship is not completely de-
fined, several investigations have confirmed that whenmac-roembolization occurs, the chance of having a neurologic
complication is significant. In the current study, visible
debris was found in 83% of the patients that had a neuro-
logic event. Thus, it can be argued that if a given variable is
going to help determine when a filter should not be used, it
must be accurate for predicting the absence of visible debris
in a high percentage of cases. Although somewhat arbitrary,
we chose a NPV of 95% as clinically acceptable. In this
scenario, the NPV is more important than the OR for
defining variables that can reliably predict the absence of
debris.
There presence of visible debris was less likely to occur
in asymptomatic patients with a moderate degree of steno-
sis. However, the NPV (0.65) for these combined variables
was inadequate for predicting the absence of debris. Unfor-
tunately, the current study failed to identify any variable
with a NPV capable of consistently predicting the absence
of debris. For example, the odds of having visible debris
were significantly elevated (16.6) when a stent with a
diameter of9mmwas used. TheNPV in this instance was
only 0.75, but it exceeded theNPV of all the other variables
assessed. This means that the filter captured visible debris in
25% of the cases, even when the stent diameter was9mm.
Not using a filter in cases where the stent diameter is 9
mm does not seem justified because macroembolization
will likely occur in 25% of these cases. In summary, we
cannot currently predict macroembolization during CAS
from pre-procedural variables, and if filters are to be used
selectively in the future, variables with a NPV 95% must
be identified.
A major limitation of the current study is that micro-
scopic analysis of the filters was not performed. It is possible
that the presence and number of microscopic debris might
have been predictable by the clinical factors assessed. How-
ever, as stated previously, our study focused primarily on
macroscopic debris because it appears to be more clinically
relevant in regards to neurologic events during CAS.
CONCLUSIONS
The current study does not address the efficacy of
cerebral protection filters for prevention of neurologic
events during CAS. Although successful in identifying
several factors associated with the presence of visible
debris, we were unable to identify any factors capable of
consistently predicting the absence of debris. If the
carotid interventionalist believes that cerebral protection
during CAS is beneficial and the lesion and anatomy are
suitable for cerebral protection, then CPD(s) should be
used routinely.
REFERENCES
1. Yadav JS, Roubin GS, Iyer S, Vitek S, King P, Jordan WD, et al.
Elective stenting of the extracranial carotid arteries. Circulation
1997;95:376-81.
2. JordanWD Jr, Voellinger DC, FisherWS, ReddenD,McDowell HA. A
comparison of carotid angioplasty with stenting versus endarterectomy
with regional anesthesia. J Vasc Surg 1998;28:397-403.
3. Diethrich EB, Ndiaye M, Reid DB. Stenting in the carotid artery: initial
experience in 110 patients. J Endovasc Surg 1996;3:42-62.
JOURNAL OF VASCULAR SURGERY
June 2005954 Sprouse, Peeters, and Bosiers4. JordanWD, Schroeder PT, FisherWS,McDowell HA. A comparison of
angioplasty vs endarterectomy in the treatment of carotid artery steno-
sis. Ann Vasc Surg 1997;13:1-8.
5. Naylor AR, Bolia A, Abbot RJ, Pye IF, Smith J, Leannard N, et al.
Randomized study of carotid angioplasty and stenting versus carotid
endarterectomy: a stopped trial. J Vasc Surg 1998;28:326-34.
6. Parodi JC, La Mura R, Ferreira LM, Mendez MV, Cersosimo H,
Schonholz C, et al. Initial evaluation of carotid angioplasty and stenting
with three different cerebral protection devices. J Vasc Surg 2000;32:
1127-36.
7. Cremonesi A, Manetti R, Setacci F, Setacci C, Castriota F. Protected
carotid stenting: clinical advantages and complications of embolic pro-
tection devices in 442 consecutive patients. Stroke 2003;34:1936-41.
8. Bosiers M, Peeters P, Verbist J, Schroe, Deloose, Lauwers G, Stockx L.
Belgian experience with FilterWire EX in the prevention of embolic
events during carotid stenting. J Endovasc Ther 2003;10:695-701.
9. Reimers B, Corvaja N, Moshiri S, Sacca S, Albiero R, Di Mario C, et al.
Cerebral protection with filter devices during carotid artery stenting.
Circulation 2001;104:12-5.
10. Cremonesi A, Castriota F. Efficacy of a nitinol filter device in the
prevention of embolic events during carotid interventions. J Endovasc
Ther 2002;9:155-9.
11. Tubler T, Schluter M, Dirsch O, Sievert H, Bosenberg I, Grube E, et al.
Balloon-protected carotid artery stenting: relationship of periproce-
dural neurological complications with the size of particulate debris.
Circulation 2001;104:2791-6.
12. Antonius Carotid Endarterectomy, Angioplasty, and Stenting Study
Group. Transcranial Doppler monitoring in angioplasty and stenting of
the carotid bifurcation. J Endovasc Ther 2003;10:702-10.
13. Spencer MP, Thomas GI, Nicholls SC, Sauvage LR. Detection of
middle cerebral artery emboli during carotid endarterectomy using
transcranial ultrasonography. Stroke 1990;21:415-23.
14. Ackerstaff RGA, Jansen C, Moll FL, Vermeulen FE, Hamerlijnck RP,
Mauser HW. The significance of microemboli detection by means of
transcranial Doppler ultrasonography monitoring in carotid endarter-
ectomy. J Vasc Surg 1995;21:963-9.
incidence of neurologic complications? And even though these15. Gaunt ME, Martin PJ, Smith JL, Rimmer T, Cherryman G, Ratliff DA,
et al. Clinical relevance of intraoperative embolization detected by
transcranial Doppler ultrasound during carotid endarterectomy: a pro-
spective study of 100 patients. Br J Surg 1994;81:1435-9.
16. Rapp JH, Pan XM, Sharp FR, Shah DM, Wille GA, Velez PM, et al.
Atheroemboli to the brain: size threshold causing acute neuronal cell
death. J Vasc Surg 2000;32:68-76.
17. Crawley F, Stygall J, Lunn S, Harrison M, Brown MM, Newman S.
Comparison of microembolism detected by transcranial Doppler and
neuropsychological sequelae of carotid surgery and percutaneous trans-
luminal angioplasty. Stroke 2000;31:1329-34.
18. Muller-Hulsbeck S, Jahnke T, Liess C, Glass C, Paulsen F, Grimm J, et
al. In vitro comparison of four cerebral protection filters for preventing
human plaque embolization during carotid interventions. J Endovasc
Ther 2002;9:793-802.
19. Mudra H, Siegler M, Haufe M, Hug M, Knape A, Meurer A, et al.
Percutaneous carotid angioplasty with stent implantation and protec-
tion device against embolism—a prospective study of 100 consecutive
cases. Dtsch Med Wochenschr 2003;128:790-6.
20. Macdonalk S, Gaines P. Current concepts of mechanical cerebral pro-
tection during precutaneous carotid intervention. Vasc Med 2003;8:
25-32.
21. Ohki T, Roubin GS, Veith FJ, Iyer SS, Brady E. Efficacy of a filter device
in the prevention of embolic events during carotid angioplasty and
stenting: an ex-vivo analysis. J Vasc Surg 1999;30:1034-44.
22. Al-Mubarak N, Roubin G, Vitek J, Iyer S. Microembolization during
carotid stenting with the distal-balloon antiemboli system. Int Angiol
2002;21:344-8.
23. Ohki T, Marin ML, Lyon RT, Berdejo GL, Soundararajan K, Ohki
M, et al. Ex vivo human carotid artery bifurcation stenting: correla-
tion of lesion characteristics with embolic potential. J Vasc Surg
1998;27:463-71.
24. Biasi G, Ferrari S, Nicolaides A, Mingazzini P, Reid D. The ICAROS
registry of carotid artery stenting. Imaging in Carotid Angioplasties and
Risk of Stroke. J Endovas Ther 2001;8:46-52.Submitted Jun 1, 2004; accepted Feb 22, 2005.DISCUSSION
Dr Michael Silva (Lubbock, Tex). Stent diameter correlated
with the increased embolic debris, was this the result of pushing
something bigger across the carotid lesion?
You used several different stents during the study. Did you
look at the size of fenestrations as a potential predictor of embolic
potential? Closed-cell designs might trap particulate better than
open-cell designs.
In patients who did not have embolic protection devices used
during the study period, 27%, was there a higher rate of clinically
evident neurologic emboli? Could the filter wires themselves be
causing some of the embolic debris?
Finally, are there patients in whom we should not be using
embolic protection devices? Describe your current approach to
selective filtration.
I’d like to congratulate the authors for the successful transat-
lantic collaboration. It is a worthy reflection of the importance of
theMarco Polo Fellowship. Additionally, I thank them for sending
me the manuscript for advance review and the Society for the
privilege of participating in the review process.
Dr Sprouse. We did look at the different types of stents that
were used, a closed-cell structure versus open-cell structure, and
found no difference. We found that the stent itself was not predic-
tive for the presence of debris. Intuitively, I would think that a
closed-cell structure, such as a self-expanding stainless steel stent,
would cause less embolic debris than an open-cell structure, but we
were unable to show that in our study.
And you did point out that of the patients in this series that
did not have placement of a distal filter device, what was thepatients did not have a distal filter, they did have some other
form of cerebral protection, whether it was a distal occlusion
balloon or flow reversal.
And your question regarding whether we selectively use cere-
bral protection, I would say that in the centers that I worked in,
cerebral protection is used routinely.
Dr Piergiorgio Cao (Perugia, Italy). We have different data
from a quite similar cohort. We have about 40% of visible debris in
our filters. My question is about the size of the stent you use. You
related stent size to the possibility of having debris. You said that in
your analysis, a stent of 9 mm or more is more commonly associ-
ated with the debris. It can be due, this factor, to the fact that you
have a high radial force in putting in a stent, so you can compress
the plaque more strongly. So the question is, what kind of oversiz-
ing do you use in correcting the plaque?
Dr Sprouse. Typically, a 10% to 20% oversize. And as you
were, we are very surprised to find that the embolic debris was
related to stent diameter. That was something we did not
expect. And I think if you look at series that have studied the
events associated with embolization during stent placement, it
is the postdilation as well as during deployment of the stent
when embolization occurs. And some of that is thought to be
due to the “cheese cutting” effect of the stent, basically com-
pressing the debris against the wall. And I think if you use a
larger stent, perhaps more of that effect occurs than if you use a
smaller stent. But I don’t have a complete explanation for it.
DrWilliamQuinones-Baldrich (Los Angeles, Calif). Have you
had an opportunity to look at the appearance of the plaque on duplex
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filter? We have been impressed that the plaques that appear echolu-
cent on duplex scan tend to be the more friable plaques with hemor-
rhage under them. And I wonder if duplex scan would not be one
factor that would correlate with the appearance of debris on the filter.
Dr Sprouse. That’s another excellent question. And there’s
actually a registry or a study that is taking place in Europe at the
moment, the ICAROS study, where they assess the gray-scale
median index of the lesion. And the earlier reports from that
study show that a GSM of less than 25 is associated with
neurologic events, and the presence of debris that is greater than
25 is not. So I think there will be some data available that the
duplex will be very important in maybe predicting patients
where a filter is going to be more beneficial. In this particular
study, we did not assess that directly.
Dr Takao Ohki (Bronx, NY). I think one particle capturedopposed to looking at the presence or absence, I think you need
to further analyze the number or the volume of embolic parti-
cles.
My question is, when we use the arterial Parodi-type occlu-
sion balloon reversal of flow, or the PercuSurge occlusion
balloon, in 100% of the cases we do see debris. Whereas with the
filters that you studied, it’s only about 50%. Does this mean that
the filters are less efficient in capturing emboli? Can you com-
ment?
Dr Sprouse. Well, we didn’t find it in 50%, it was in 60.4%
that we found macroscopic debris. I think with the filters, you
obviously are not going to capture all debris, especially if the
debris is less than 100 to 200 microns, which is the size of a
pore. But what’s been shown in both human and animal studies
is that the smaller debris is clinically insignificant. So it’s only thein a filter versus 20 or 30 is quite different. And I think, as larger debris that is associated with neurologic complications.
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